Why would the European Union threaten to block coronavirus vaccine exports? EU countries have long been waiting for the AstraZeneca vaccine – and now, at the last, it has been snatched from their grasp. In August, the European Commission announced that it had secured 300 million doses of the AstraZeneca jab, with an option for a further 100 million. With enough doses for 200 million people, the supply could have vaccinated roughly half of all EU citizens. It brought the European Commission's highly ambitious target of vaccinating 70 percent of all EU citizens by the summer, and even a revival of the tourism trade, into the realms of possibility. The European Medicines Agency is expected to grant market authorisation at the end of the week, meaning doses could be shipped out to the member states. But on Friday, AstraZeneca wrote to the EU executive saying it had supply chain problems and would not be able to fulfil its contractual obligations. The news was a bitter blow to the commission, which has led negotiations in the EU joint vaccine procurement process, but especially for the bloc's member states. National governments are now faced with the unenviable task of explaining to their voters why the promised vaccines are not coming. Many EU countries bet on the AstraZeneca jab, foregoing its more expensive and difficult to store rivals.That made it an attractive proposition for poorer member states, and easier to get to more remote areas than those requiring complicated storage technology. They were waiting for the AstraZeneca vaccine, despite growing pressure from their voters. Dissatisfaction with coronavirus restrictions is growing in Europe, with the Dutch rioting against a coronavirus curfew at the weekend.